CDIO (Cardio Diagnostics Holdings) 5-Year Sortino Ratio: N/A (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDIO Cardio Diagnostics Holdings Inc CDIO
51 GF Score
Price $1.66
GF Value $2.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cardio Diagnostics Holdings 5-Year Sortino Ratio?

The 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. As of today (2026-08-07), Cardio Diagnostics Holdings's 5-Year Sortino Ratio is Not available.


Cardio Diagnostics Holdings  (NAS:CDIO) 5-Year Sortino Ratio Explanation

The 5-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past five year. It is calculated as the annualized result of the average five-year monthly excess returns divided by the standard deviation of negative returns in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Cardio Diagnostics Holdings 5-Year Sortino Ratio Related Terms


CDIO vs ERNA, LABT, JAGX: 5-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Cardio Diagnostics Holdings's 5-Year Sortino Ratio, along with its competitors' market caps and 5-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings 5-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's 5-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's 5-Year Sortino Ratio falls into.


CDIO
51GF Score
Cardio Diagnostics Holdings Inc CDIO
5-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardio Diagnostics Holdings 5-Year Sortino Ratio Calculation

The 5-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last five year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 5-Year Sortino Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past five year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?

Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued. The current stock price of $1.66 is trading 40.1% below its estimated GF Value™ of $2.77. GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.

Key valuation signals for CDIO:

  • 5-Year Sortino Ratio: N/A
  • GF Value™: $2.77 vs. price of $1.66 (40.1% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cardio Diagnostics Holdings Business Description

Address 311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
51GF Score

Get the complete analysis for CDIO

5-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.66
Price
$2.77
GF Value